Louise Bach Callesen

Dr. Louise Bach Callesen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
LCLouise Bach Callesen
Louise Bach Callesen
JHJulian Hamfjord
Julian Hamfjord
ABAnders K. Boysen
Anders K. Boysen
NPNiels Pallisgaard
Niels Pallisgaard
TGTormod K. Guren
Tormod K. Guren
KSKaren-Lise Spindler
Karen-Lise Spindler

1 May 2021 in Clinical Oncology
Verified
Journal Article
Closed access
LCLouise Bach Callesen
Louise Bach Callesen
ASA. Safwat
A. Safwat
HRH.K. Rose
H.K. Rose
FSF.B. Sørensen
F.B. Sørensen
TBT. Baad-Hansen
T. Baad-Hansen
NAN. Aggerholm-Pedersen
N. Aggerholm-Pedersen

2 November 2022 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
LCLouise Bach Callesen
Louise Bach Callesen
TTTana Takacova
Tana Takacova
JHJulian Hamfjord
Julian Hamfjord
FWFlorian Würschmidt
Florian Würschmidt
KOKarl J. Oldhafer
Karl J. Oldhafer
KSKaren-Lise G. Spindler
Karen-Lise G. Spindler
Background: Loco-regional treatment strategies of colorectal cancer (CRC) metastases are evolving, but biological markers that can benefit patients and assist physicians in clinical decisions are lacking. The primary objective of this systematic review and meta-analysis is to investigate the current knowledge on circulating DNA and its clinical utility in predicting outcomes in patients undergoing loco-regional treatment of CRC metastases. Methods: A systematic search of PubMed, Embase, and Cochrane Central Register of Controlled Trials was conducted on March 22, 2022. We included studies on patients undergoing loco-regional treatment of CRC metastases reporting the predictive or prognostic value of circulating DNA in the blood. Hazard ratios (HR) were pooled in separate random-effects meta-analyses to investigate if pre- or post-ablation measurements of circulating DNA were associated with survival. The risk of bias was assessed according to the Quality in Prognosis Studies tool. Results: Twenty-eight studies with 2868 patients were included, of which 16 studies were eligible for meta-analyses. As expected in this new research field, a majority of included studies ( n = 21/28) had a high risk of bias in at least one domain. Circulating DNA above the cutoff in a plasma sample taken before loco-regional treatment was associated with a short recurrence-free survival [pooled HR = 2.8, 95% confidence interval (CI) 1.4–5.7, n = 162] and overall survival (pooled HR = 4.7, 95% CI 1.1–20.6, n = 105). Circulating DNA above the cutoff in a plasma sample taken after loco-regional treatment was associated with a short recurrence-free survival (pooled HR = 4.5, 95% CI 3.4–6.1, n = 569) and overall survival (pooled HR = 7.5, 95% CI 2.0–27.3, n = 161). There was limited data on the association between dynamics in circulating DNA and outcome. Conclusions: Measurements of circulating DNA can be valuable when selecting and monitoring patients undergoing loco-regional treatment of CRC metastases. Studies designed to investigate the true clinical utility of circulating DNA in the context of various ablation modalities are warranted. The review has been registered at PROSPERO (ID: CRD42022320032)

2 September 2022 in Acta Oncologica
Verified
Journal Article
Closed access
LCLouise Bach Callesen
Louise Bach Callesen
THTorben Frøstrup Hansen
Torben Frøstrup Hansen
RARikke Fredslund Andersen
Rikke Fredslund Andersen
NPNiels Pallisgaard
Niels Pallisgaard
SKStine Kramer
Stine Kramer
KSKaren-Lise Spindler
Karen-Lise Spindler
In oligometastatic colorectal cancer (OCRC), there can be a curative potential from treating metastases [1,2]. Some patients obtain long-term survival whereas others show aggressive biology with ea...

22 September 2023 in Acta Oncologica
Verified
Journal Article
Closed access
LCLouise Bach Callesen
Louise Bach Callesen
THTorben Frøstrup Hansen
Torben Frøstrup Hansen
RARikke Fredslund Andersen
Rikke Fredslund Andersen
NPNiels Pallisgaard
Niels Pallisgaard
SKStine Kramer
Stine Kramer
KSKaren-Lise Spindler
Karen-Lise Spindler
Patients with detectable ctDNA after radical-intent treatment of metastatic spread from colorectal cancer (mCRC) have a very high risk of recurrence, which may be prevented with intensified adjuvant chemotherapy (aCTh). In the OPTIMISE study, we investigate ctDNA-guided aCTh after radical-intent treatment of mCRC. Here we present results from the preplanned interim analysis. The study is an open-label 1:1 randomized clinical trial comparing ctDNA-guided aCTh against standard of care (SOC), with a run-in phase investigating feasibility measures. Key inclusion criteria; radical-intent treatment for mCRC and clinically eligible for triple-agent chemotherapy. Patients underwent a PET-CT scan before randomization. ctDNA analyses of plasma samples were done by ddPCR, detecting CRC-specific mutations and methylation of the NPY gene. In the ctDNA-guided arm, ctDNA positivity led to an escalation strategy with triple-agent chemotherapy, and conversely ctDNA negativity led to a de-escalation strategy by shared-decision making. Patients randomized to the standard arm were treated according to SOC. Feasibility measures for the run-in phase were; the inclusion of 30 patients over 12 months in two Danish hospitals, compliance with randomization >80%, rate of PET-CT-positive findings 80%. Thirty-two patients were included. The rate of PET-CT-positive cases was 22% (n = 7/32). Ninety-seven percent of the patients were randomized. Fourteen patients were randomly assigned to SOC and sixteen to ctDNA-guided adjuvant treatment and follow-up. All analyses of baseline plasma samples in the ctDNA-guided arm passed the quality control, and 19% were ctDNA positive. The median time to result was three working days. All ctDNA-positive patients were eligible for triple-agent chemotherapy. The study was proven to be feasible and continues in the planned large-scale phase II trial. Results from the OPTIMISE study will potentially optimize the adjuvant treatment of patients undergoing radical-intent treatment of mCRC, thereby improving survival and reducing chemotherapy-related toxicity.

30 October 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LCLouise Bach Callesen
Louise Bach Callesen
ABAnders Kindberg Boysen
Anders Kindberg Boysen
RARikke Fredslund Andersen
Rikke Fredslund Andersen
RDRikke Beese Dalby
Rikke Beese Dalby
KSKaren-Lise Garm Spindler
Karen-Lise Garm Spindler
This explorative prospective observational pilot study investigated if suggested risk factors, rectal cancer and lung metastases, could add to a relevant detection rate of asymptomatic brain metastases (BM) from colorectal cancer (CRC). Secondary, prognostic biological aspects were investigated by translational analysis of plasma samples. The study enrolled patients with rectal cancer and lung metastases. At inclusion, patients underwent a standard MRI scan of the brain. Cell-free DNA (cfDNA) level was measured by a direct fluorescence assay (DFA), and circulating tumor DNA (ctDNA) by ddPCR. BM was detected in one of twenty-nine included patients. Patients had higher cfDNA levels than healthy subjects (p < 0.01). Patients with the primary tumor in situ had higher cfDNA levels than those with resected primary tumor (p < 0.01). Patients with liver involvement had higher cfDNA levels (p = 0.12) and circulating tumor DNA levels (p = 0.01) than those without liver involvement. In conclusion, the modest incidence of BM does not justify routine MRI of the brain in this selected population. cfDNA by DFA could be a valuable tool when planning treatment and follow-up for CRC patients. Future studies should focus on identifying further characteristics and biomarkers associated with a high risk of BM, enhancing the possibility for early intervention.